Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Frontiers in Public Health|April 3, 2023
Content and sentiment surveillance (CSI): A critical component for modeling modern epidemicsShi Chen, Shuhua Jessica Yin, Yuqi Guo, et al.
Basic & Clinical Pharmacology & Toxicology|October 28, 2010
Concomitant administration of BILR 355/r with emtricitabine/tenofovir disoproxil fumarate increases exposure to emtricitabine and tenofovir: a randomized, open-label, prospective studyFenglei Huang, Paul Scholl, David B Huang, et al.
Advances in Experimental Medicine and Biology|November 28, 2015
A Bioenergetics Approach to Understanding the Population Consequences of Disturbance: Elephant Seals as a Model SystemDaniel P Costa, Lisa Schwarz, Patrick Robinson, et al.
Plos Medicine|October 28, 2009
Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trialJames A McIntyre, Mark Hopley, Daya Moodley, et al.
Implementation Science Communications|April 24, 2025
The peer paradox: Perspectives from HIV service providers to inform the implementation of an enhanced social network strategy for black sexual and gender minorities-a qualitative studyMeagan C Zarwell, Ian Dale, Eunice Okumu, et al.
Journal of Medical Internet Research|March 14, 2021
A Multimodality Machine Learning Approach to Differentiate Severe and Nonsevere COVID-19: Model Development and ValidationYuanfang Chen, Liu Ouyang, Forrest S Bao, et al.
The Journal of Infectious Diseases|February 25, 2003
A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1Dhayendre Moodley, Jagidesa Moodley, Hoosen Coovadia, et al.
Plos One|January 6, 2016
Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter TrialDavid A Cooper, Damien V Cordery, Roberto Zajdenverg, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|April 21, 2004
Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adultsGail Skowron, Gifford Leoung, David B Hall, et al.
AIDS Patient Care and Stds|November 13, 2023
Uptake and Discontinuation of Pre-Exposure Prophylaxis Among Uninsured Transgender and Cisgender Women: A Public-Private Partnership Model in North CarolinaMeagan Zarwell, Brian Witt, Sebastian Marin-Cespedes, et al.
Pageof 5